Genelux to Join BTIG Virtual Biotechnology Conference 2024 Fireside Chat

Genelux Corporation, a company specializing in immuno-oncology, announced that its President, CEO, and Chairman, Thomas Zindrick, will be discussing various clinical-stage programs, recent developments, and future milestones at BTIG’s Virtual Biotechnology Conference 2024. The event will feature a conversation between Zindrick and Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, scheduled for 12:00 p.m. ET on Tuesday, August 6, 2024.

Genelux Corporation is a biopharmaceutical company in the late stages of clinical development. The company is focused on creating a pipeline of next-generation oncolytic immunotherapies aimed at treating patients with aggressive or hard-to-treat solid tumors. Their most advanced product candidate is Olvi-Vec (olvimulogene nanivacirepvec). Olvi-Vec is a proprietary modified strain of the vaccinia virus and is currently being tested in a Phase 3 trial known as OnPrime/GOG-3076. This multi-center, randomized, open-label Phase 3 registrational trial is designed to evaluate the efficacy and safety of Olvi-Vec when combined with platinum-doublet chemotherapy and bevacizumab. This combination is being compared to the physician's choice of chemotherapy and bevacizumab in patients who have platinum-resistant or refractory ovarian cancer.

Central to Genelux’s discovery and development efforts is its proprietary CHOICE™ platform. This platform has enabled the company to develop a vast library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!